PMID- 34965081
OWN - NLM
STAT- MEDLINE
DCOM- 20211231
LR  - 20211231
IS  - 0042-465X (Print)
IS  - 0042-465X (Linking)
VI  - 137
IP  - 6
DP  - 2021
TI  - [Potential pitfalls of anti-VEGF therapy of neovascular age-related macular 
      degeneration].
PG  - 149-156
LID - 10.17116/oftalma2021137061149 [doi]
AB  - When administering anti-VEGF therapy for neovascular age-related macular 
      degeneration (nAMD), it is necessary to take into account the fact that treatment 
      outcomes - in addition to factors associated with the disease itself - may be 
      affected by progressive concomitant conditions (for example, macular atrophy) and 
      possible adverse events (AEs). The latter can be divided into two large groups: 
      non-inflammatory and inflammatory. Intraocular inflammation (IOI) is a rare but 
      potentially dangerous AE of anti-VEGF therapy, which can include endophthalmitis, 
      early sterile inflammation and retinal vasculitis. Raising awareness about 
      inflammatory AEs is becoming even more important due to the sheer number of 
      intravitreal injections performed, as well as the frequency of cases of IOI when 
      using new anti-VEGF drugs. The new anti-VEGF drug Brolucizumab is associated with 
      the development of retinal vasculitis, which is considered a type III and IV 
      hypersensitivity reaction (involving cellular and humoral immune responses, 
      respectively). The article presents an overview of publications on the 
      mechanisms, clinical manifestations, differentiation, and methods of treatment of 
      various types of IOI.
FAU - Kovalevskaya, M A
AU  - Kovalevskaya MA
AUID- ORCID: 0000-0001-8000-5757
AD  - Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia.
FAU - Pererva, O A
AU  - Pererva OA
AUID- ORCID: 0000-0003-4183-2420
AD  - Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia.
FAU - Roldugin, A A
AU  - Roldugin AA
AUID- ORCID: 0000-0002-7764-3739
AD  - Voronezh Regional Clinical Ophthalmological Hospital, Voronezh, Russia.
FAU - Kartamyshev, E G
AU  - Kartamyshev EG
AUID- ORCID: 0000-0001-9089-8851
AD  - Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia.
LA  - rus
PT  - Journal Article
TT  - Vozmozhnye problemy anti-VEGF-terapii neovaskulyarnoi vozrastnoi makulyarnoi 
      degeneratsii.
PL  - Russia (Federation)
TA  - Vestn Oftalmol
JT  - Vestnik oftalmologii
JID - 0415216
RN  - 0 (Angiogenesis Inhibitors)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/adverse effects
MH  - *Endophthalmitis/drug therapy
MH  - Humans
MH  - Intravitreal Injections
MH  - *Macular Degeneration/diagnosis/drug therapy
MH  - Ranibizumab/adverse effects
MH  - Visual Acuity
MH  - *Wet Macular Degeneration/drug therapy
OTO - NOTNLM
OT  - age-related macular degeneration
OT  - intraocular inflammation
OT  - neovascular age-related macular degeneration
OT  - retinal vasculitis
OT  - sterile inflammation
EDAT- 2021/12/30 06:00
MHDA- 2022/01/01 06:00
CRDT- 2021/12/29 16:05
PHST- 2021/12/29 16:05 [entrez]
PHST- 2021/12/30 06:00 [pubmed]
PHST- 2022/01/01 06:00 [medline]
AID - 10.17116/oftalma2021137061149 [doi]
PST - ppublish
SO  - Vestn Oftalmol. 2021;137(6):149-156. doi: 10.17116/oftalma2021137061149.